By Colin Kellaher
Mural Oncology shares more than doubled in premarket trading Tuesday after the clinical-stage immuno-oncology company said it will explore strategic alternatives and shed the bulk of its staff after throwing in the towel on its lead product candidate.
Mural on Tuesday said it is ending all clinical development of its proposed nemvaleukin alfa cancer treatment and focusing on maximizing shareholder value.
The Dublin-based company said it plans to cut 104 jobs, or roughly 90% of its workforce, resulting on costs of $9 million to $10 million.
Mural said the move follows a review of data from its Phase 2 study of nemvaleukin alfa in melanoma, as well as previously announced results from a Phase 3 study in platinum-resistant ovarian cancer.
Mural said it plans to explore potential options, including a sale of the company, adding that it hasn't received any approaches nor is it in active talks with any potential buyer.
Mural sports a market capitalization of about $17.75 million based on Monday's closing price of $1.03, well below the $144.4 million in cash, equivalents and marketable the company had on hand at the end of 2024.
Shares of Mural were recently up 104% to $2.10 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 15, 2025 08:54 ET (12:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。